Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines
- PMID: 15205948
- PMCID: PMC12161872
- DOI: 10.1007/s00432-004-0575-6
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines
Abstract
Purpose: The addition of oxaliplatin or CPT-11 to 5-FU has become common practice in the treatment of colorectal cancer. It is not known, however, which fluoropyrimidine drug (5-FU, FUdR, or FUR) will produce superior cytotoxicity when combined with either oxaliplatin or CPT-11. The purpose of the study was to determine the effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of all three fluoropyrimidines.
Methods: HT-29 cells were exposed for 2 h to IC(10), IC(30), and IC(70) of oxaliplatin and CPT-11. Subsequently, cells were exposed for 24 h to IC(10), IC(30), and IC(70) of 5-FU, FUdR, and FUR. Cytotoxicity was measured by the MTT assay. Nucleic acid incorporation of [(3)H]fluoropyrimidine was then compared in the presence and absence of oxaliplatin or CPT-11 pretreatment.
Results: Synergistic cytotoxicity was displayed when IC(30) of oxaliplatin or CPT-11 was combined with IC(10) and IC(30) of the fluoropyrimidines. One fluoropyrimidine did not achieve superior cytotoxicity over the others. After pretreatment with oxaliplatin or CPT-11, cytotoxic antagonism was observed as the concentration of a fluoropyrimidine increased up to IC(70). The increasing cytotoxic antagonism correlated with decreases in fluoropyrimidine nucleic acid incorporation. The most significant incorporation difference existed within the 5-FU treated group.
Conclusions: No single fluoropyrimidine is more cytotoxically effective over the others when combined with oxaliplatin or CPT-11. Correlation of cytotoxic antagonism to the inhibition of fluoropyrimidine nucleic acid incorporation implies difficulties in drug transport and/or metabolism only after oxaliplatin or CPT-11 pretreatment.
Figures

Similar articles
-
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150. Health Technol Assess. 2008. PMID: 18462574
-
Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article.
-
Oral versus intravenous fluoropyrimidines for colorectal cancer.Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD008398. doi: 10.1002/14651858.CD008398.pub2. Cochrane Database Syst Rev. 2017. PMID: 28752564 Free PMC article.
-
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419291 Free PMC article.
-
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.Cochrane Database Syst Rev. 2016 Feb 12;2(2):CD008593. doi: 10.1002/14651858.CD008593.pub3. Cochrane Database Syst Rev. 2016. PMID: 26869023 Free PMC article.
Cited by
-
Antibacterial mechanism of areca nut essential oils against Streptococcus mutans by targeting the biofilm and the cell membrane.Front Cell Infect Microbiol. 2023 Aug 28;13:1140689. doi: 10.3389/fcimb.2023.1140689. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37701779 Free PMC article.
-
Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.Ther Adv Med Oncol. 2010 May;2(3):161-74. doi: 10.1177/1758834010365061. Ther Adv Med Oncol. 2010. PMID: 21789132 Free PMC article.
References
-
- Agarwal RP, Han T, Fernandez M (2001) Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61:39–47 - PubMed
-
- Ansfield FJ, Curreri AR (1963) Further clinical comparison between 5-Fluorouracil (5-FU) and 5-fluoro-2’-deoxyuridine (5-FUDR). Cancer Chemother Rept 32:101–105 - PubMed
-
- Arisawa Y, Sutanto-Ward E, Dalton RD, Sigurdson ER (1994) Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. J Surg Oncol 56:75–80 - PubMed
-
- Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics 1994. CA Cancer J Clin 44:7–26 - PubMed
-
- Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK (1976) Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 60:1277–1279 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources